interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Revefenacin

Generic competition · all medicines · read 12 November 2026

Is there a generic of Revefenacin, and who makes it?

Revefenacin appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Revefenacin1 dosage-form group in the Orange Book
0generic makers listed
  1. Revefenacin appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Solution, Inhalation

Brand listed, no generic listed as marketed

Brand listed as marketed: Yupelri. No generic is listed as marketed.

20152020202520302035204001brand 2018data datePatent 7288657 listed to expire 31 October 2028Patent 11008289 listed to expire 14 July 2030Patent 11858898 listed to expire 14 July 2030Patent 10550081 listed to expire 14 July 2030Patent 9765028 listed to expire 14 July 2030Patent 11691948 listed to expire 14 July 2030Patent 8541451 listed to expire 25 August 2031Patent 12285417 listed to expire 29 August 2039Patent 12048692 listed to expire 29 August 2039Patent 11484531 listed to expire 23 October 2039
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 31 October 2028Patent 7288657 drug substance
  • 14 July 2030Patent 11008289
  • 14 July 2030Patent 11858898 drug substance
  • 14 July 2030Patent 10550081 drug substance
  • 14 July 2030Patent 9765028 drug substance
  • 14 July 2030Patent 11691948 drug product
  • 25 August 2031Patent 8541451 drug substance
  • 29 August 2039Patent 12285417

2 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.